文献速递艾滋病与性传播感染

比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺(BIC/FTC/TAF)在HIV感染者中的有效性、安全性和停药率:基于真实世界数据的系统综述与Meta分析

Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis.
PubMed 文献 · J Antimicrob Chemother · 2024-01-01

该系统综述与Meta分析纳入12篇真实世界研究出版物(792例初治和6732例经治HIV感染者),评估BIC/FTC/TAF的病毒学抑制与停药率。初治者48周病毒载量<50 copies/mL比例为97%(95%CI 89-100),经治者为95%(95%CI 94-96),经治者总停药率3%(95%CI 2-5),副作用停药率1%(95%CI 0-2)。

要点

  • 初治HIV感染者48周病毒学抑制率为97%(95%CI 89-100)。
  • 经治HIV感染者48周病毒学抑制率为95%(95%CI 94-96),所有研究抑制率>93%。
  • 经治者48周总停药率3%(95%CI 2-5),副作用相关停药率1%(95%CI 0-2)。

核心结论

  • 真实世界研究显示,BIC/FTC/TAF在初治和经治HIV感染者(包括既往检出M184V替换者)中停药率低且病毒学抑制率高。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、PubMed和Embase截至2024年1月31日的出版物和会议摘要,纳入报告BIC/FTC/TAF回顾性真实世界使用的12篇出版物(792例初治和6732例经治HIV感染者)。

主要发现

  • 3篇报告主要终点的出版物共507例初治参与者,48周病毒载量<50 copies/mL比例为97%(95%CI 89-100)。
  • 9篇报告主要终点的出版物共4946例经治参与者,48周病毒载量<50 copies/mL比例为95%(95%CI 94-96),所有研究抑制率>93%。
  • 经治者48周总停药率为3%(95%CI 2-5),因副作用停药率为1%(95%CI 0-2)。
  • 4篇出版物共151例既往存在M184V替换的经治者,48周抑制率为95%(95%CI 88-100)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The use of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) is based on the results of robust clinical trials. OBJECTIVES: To assess the effectiveness and safety of BIC/FTC/TAF in treatment-naïve (TN) and treatment-experienced (TE) people with HIV using available real-world cohort studies. METHODS: Systematic review and meta-analysis of publications and communications identified via Boolean search in Medline, PubMed and Embase, and conference abstracts reporting retrospective real-world use of BIC/FTC/TAF, published until 31 January 2024. The primary endpoint was the proportion of TN and TE people with HIV with viral load (VL) < 50 copies/mL at 48 weeks while on treatment. RESULTS: Of the 38 identified publications and conference abstracts, for the present analysis we included 12 publications (comprising 792 TN and 6732 TE individuals). For the three publications including 507 TN participants reporting the primary outcome, VL suppression was 97% [95% confidence intervals (CI): 89-100]. For the nine publications including 4946 TE participants reporting the primary outcome, VL suppression was 95% (95% CI: 94-96), with suppression >93% in all studies. Total discontinuations at 48 weeks in TE individuals were 3% (95% CI: 2-5), 1% (95% CI: 0-2) due to side effects. A total of four publications with 151 TE individuals with previous presence of M184V substitution were identified, reporting a suppression rate at 48 weeks of 95% (95% CI: 88-100). CONCLUSIONS: Real-world studies demonstrate low discontinuation rates and high rates of virologic suppression in individuals treated with BIC/FTC/TAF, both TN and TE with and without previous detection of M184V substitution.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Chivite I, Berrocal L, de Lazzari E, et al. Effectiveness, safety and discontinuation rates of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) in people with HIV using real-world data: a systematic review and meta-analysis. J Antimicrob Chemother. 2024. PMID: 38758191. doi:10.1093/jac/dkae138

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。